Last update Oct. 29, 2024

Биластин

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Second generation antihistamine without sedative or antimuscarinic effect. Use in allergic rhinitis and conjunctivitis and urticaria. Oral administration once daily. ( AEMPS 2016, Wolthers 2013, Scaglione 2012, Conen 2011, Church 2011)

At the date of last update we found no published data on its excretion in breast milk. 

Its lack of sedative effect because it does not cross the blood-brain barrier (Scaglione 2012, Church 2011) and its pharmacokinetic profile (Togawa 2016, AEMPS 2016, Sádaba 2013), -high percentage of plasma protein binding and volume of distribution and medium oral bioavailability-, make it unlikely to cause problems for the infant.

Until more data on this drug in relation to breastfeeding are known, safer alternatives are preferable, especially during the first month and in the case of mothers of premature infants.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Биластин is Bilastine in Cyrillic.

Is written in other languages:

Group

Биластин belongs to this group or family:

Tradenames

Main tradenames from several countries containing Биластин in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 61 %
Molecular weight 464 daltons
Protein Binding 84 - 90 %
VD 4.1 - 4.5 l/Kg
pKa 4.06 -
Tmax 0.9 - 1.4 hours
10.9 - 14.5 hours

References

  1. AEMPS. Bilastina. Ficha técnica 2016 Full text (in our servers)
  2. Togawa M, Yamaya H, Rodríguez M, Nagashima H. Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. Clin Drug Investig. 2016 Abstract Full text (link to original source) Full text (in our servers)
  3. Sádaba B, Gómez-Guiu A, Azanza JR, Ortega I, Valiente R. Oral availability of bilastine. Clin Drug Investig. 2013 Abstract
  4. Wolthers OD. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria. Biomed Res Int. 2013 Abstract Full text (link to original source) Full text (in our servers)
  5. Scaglione F. Safety profile of bilastine: 2nd generation H1-antihistamines. Eur Rev Med Pharmacol Sci. 2012 Abstract Full text (link to original source) Full text (in our servers)
  6. Church MK. Safety and efficacy of bilastine: a new H(1)-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opin Drug Saf. 2011 Abstract
  7. Conen S, Theunissen EL, Van Oers AC, Valiente R, Ramaekers JG. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol. 2011 Abstract

Total visits

2,320

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM